Efficacy and in vitro pharmacological assessment of novel N -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors
Open Access
- 31 January 2025
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (1) , e0145524
Abstract
We previously reported N -hydroxypyridinedione (HPD) compounds with mid-nanomolar efficacy and selectivity indexes around 300 against hepatitis B virus (HBV) replication. However, they lack pharmacological evaluation. Here, we report in vitro anti-HBV efficacy, cytotoxicity, and pharmacological characterization of 29 novel HPDs within seven subgroups. The best two compounds had EC 50 s of 61 and 190 nM and selectivity indexes of 526 and 1,071. Compounds with one halogen on the major R group were most effective and compounds with large ether R groups were most cytotoxic. Compounds were not cytotoxic in primary human hepatocytes. All compounds were freely soluble in pHs reflecting plasma (7.4) and the gastrointestinal tract (5 and 6.5). Almost all highly soluble compounds were passively permeable at pH 5.0 and 7.4. Only 2 of 11 compounds tested were likely to be effluxed by p-glycoprotein. The most potent HPDs inhibited HBV replication over human ribonuclease H1 activity by 10-fold. Four of 19 compounds inhibited CYP2D6 >50%, but their CYP2D6 IC 50 s were >8× higher than their anti-HBV EC 50 . No compound substantially inhibited CYP3A4. Thirteen of 15 compounds had human microsomal half-lives >30 min with medium to low rates of intrinsic clearance. Eleven of 12 compounds bound plasma proteins by ≥80%; however, effects against HBV replication for only one would likely be physiologically relevant. These results identify two lead candidate HPDs with pharmacological characteristics resembling commercially available drugs that are suitable for in vivo pharmacological and efficacy studies.Keywords
Funding Information
- HHS | National Institutes of Health (R01 AI150610)
- Gilead Sciences (ASKLEPIOS)
This publication has 54 references indexed in Scilit:
- Identification and assessment of the 1,6-dihydroxy-pyridin-2-one moiety as privileged scaffold for HBV ribonuclease H inhibitionAntiviral Research, 2024
- In vitro evaluation of tropolone absorption, metabolism, and clearanceAntiviral Research, 2023
- Predicted structure of the hepatitis B virus polymerase reveals an ancient conserved protein foldProtein Science, 2022
- Physical methods for enhancing drug absorption from the gastrointestinal tractAdvanced Drug Delivery Reviews, 2021
- HBV replication inhibitorsAntiviral Research, 2020
- Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitorsAntiviral Research, 2019
- Inhibition of hepatitis B virus replication by N -hydroxyisoquinolinediones and related polyoxygenated heterocyclesAntiviral Research, 2017
- The hepatitis B virus ribonuclease H as a drug targetAntiviral Research, 2015
- Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin–ligand complexesBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activityAntiviral Research, 2013